These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 22499297)
1. The expression of immunohistochemical markers estrogen receptor, progesterone receptor, Her-2-neu, p53 and Ki-67 in epithelial ovarian tumors and its correlation with clinicopathologic variables. Sylvia MT; Kumar S; Dasari P Indian J Pathol Microbiol; 2012; 55(1):33-7. PubMed ID: 22499297 [TBL] [Abstract][Full Text] [Related]
2. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Wong KK; Lu KH; Malpica A; Bodurka DC; Shvartsman HS; Schmandt RE; Thornton AD; Deavers MT; Silva EG; Gershenson DM Int J Gynecol Pathol; 2007 Oct; 26(4):404-9. PubMed ID: 17885490 [TBL] [Abstract][Full Text] [Related]
3. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797 [TBL] [Abstract][Full Text] [Related]
4. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors. Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733 [TBL] [Abstract][Full Text] [Related]
5. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma. Ali-Fehmi R; Che M; Khalifeh I; Malone JM; Morris R; Lawrence WD; Munkarah AR Cancer; 2003 Oct; 98(7):1423-9. PubMed ID: 14508829 [TBL] [Abstract][Full Text] [Related]
6. Clinical factors and biomarkers in ovarian tumors development. Vrabie CD; Petrescu A; Waller M; Dina I Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637 [TBL] [Abstract][Full Text] [Related]
7. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms. Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965 [TBL] [Abstract][Full Text] [Related]
8. HER-2/neu overexpression in breast cancer: an immunohistochemical study including correlations with clinicopathologic parameters, p53 oncoprotein and cathepsin-D. Korkolis D; Ardavanis A; Yotis J; Kyroudi A; Gorgoulis V; Kittas C Anticancer Res; 2001; 21(3C):2207-12. PubMed ID: 11501848 [TBL] [Abstract][Full Text] [Related]
9. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity. Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106 [TBL] [Abstract][Full Text] [Related]
10. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma. Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D J BUON; 2007; 12(1):99-104. PubMed ID: 17436409 [TBL] [Abstract][Full Text] [Related]
11. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas]. Shao HL; Shen DH; Xue WC; Li Y; Yu YZ Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760 [TBL] [Abstract][Full Text] [Related]
12. Steroid receptors and hormones in relation to cell proliferation and apoptosis in poorly differentiated epithelial ovarian tumors. Lindgren P; Bäckström T; Mählck CG; Ridderheim M; Cajander S Int J Oncol; 2001 Jul; 19(1):31-8. PubMed ID: 11408919 [TBL] [Abstract][Full Text] [Related]
13. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P Breast J; 2005; 11(4):278-80. PubMed ID: 15982396 [TBL] [Abstract][Full Text] [Related]
14. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary. Karaferic A; Jovanovic D; Jelic S J BUON; 2009; 14(4):635-9. PubMed ID: 20148455 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554 [TBL] [Abstract][Full Text] [Related]
16. Expression of the estrogen and progesterone receptors as prognostic factor in serous ovarian cancers. Buchynska LG; Iurchenko NP; Grinkevych VM; Nesina IP; Chekhun SV; Svintsitsky VS Exp Oncol; 2009 Mar; 31(1):48-51. PubMed ID: 19300417 [TBL] [Abstract][Full Text] [Related]